BioCorRx (BICX) EBITDA (2010 - 2026)

BioCorRx has disclosed EBITDA across 17 years of filings, most recently posting -$953390.0 for Q1 2026.

• EBITDA for Q1 2026 came in at -$953390.0, down 2.06% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.0 million (up 0.94% YoY), and the FY2025 annual result was -$4.8 million, up 5.38% from the prior year.
• EBITDA came in at -$953390.0 for Q1 2026 at BioCorRx, down from -$707526.0 in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$707526.0 in Q4 2025 to a low of -$1.9 million in Q3 2025.
• The 5-year median for EBITDA is -$1.0 million (2023), against an average of -$1.1 million.
• Across the five-year window, EBITDA jumped 37.19% in 2022 and plunged 73.04% in 2024, its largest moves.
• BioCorRx's EBITDA stood at -$1.2 million in 2022, then soared by 30.78% to -$816292.0 in 2023, then slumped by 36.23% to -$1.1 million in 2024, then soared by 36.38% to -$707526.0 in 2025, then plunged by 34.75% to -$953390.0 in 2026.
• The last three EBITDA figures came in at -$953390.0 (Q1 2026), -$707526.0 (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.